Home
Advertisement & Sponsorship Options
Download Our Media Kit
Continued Medical Education
Cancer A – Z
Drug Developmemt Technologies
A Novel Technology based on Somatic Hypermutation (SHM)
Editorial Advisory Board
Join Our Editorial Advisory Board
Contact Us
Terms and Conditions
Publications
ADC Review | J. Antibody-drug Conjugates
Resources for For Clinicians
Drug Map (ADC)
Peer Review Articles
The Review
Changing Strategies in the War on Cancer
Changing Strategies in the War on Cancer – Episode 1
Changing Strategies in the War on Cancer – Episode 2
Changing Strategies in the War on Cancer – Episode 3
Centers of the Cancer Universe: A Half-Century of Progress Against Cancer
Journal of CAR T-Cell Therapy
About CAR T-cells
Frequently Asked Questions
Types of Articles
Submit a Manuscript
The Onco’Zine Brief
The Network
The Episodes
How to Support The Onco’Zine Brief
Corporate Underwriting and Sponsorship
The Onco’Zine Dossier
Thalidomide: A History
Thalidomide: In the Shadow of Death
Controversy: The involvement of Ciba AG in the development of Thalidomide
Thalidomide’s Secret Past: The Link with Nazi Germany
Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer
Smoking and Health
New Surgeon General’s Report Presents the Unfiltered Truth About Tobacco
Smoking and the Lost Legacy of the First Surgeon General’s Report on Smoking and Health
Tobacco Control in the United States Has Saved 8 Million Lives In Last 50 Years
Tobacco Companies are Finally Moving Closer to Revealing the Truth about Smoking
The Harmful Effects of Smoking: The Public Denial in the Early-mid 1960s
Drug Approvals 2017 – 2020
Oncology & Hematology – FDA Drug Approvals 2018
Oncology & Hematology – FDA Drug Approvals 2019
Oncology & Hematology – FDA Drug Approvals 2020
Articles
Latest Articles
Expert Interviews
Editorials and Commentaries
Eric Rosenthal Reports
Publications
News
Business & Economics
Clinical Development
Conference Coverage
The Onco’Zine Brief
The Episodes
National Advertising
Agenda
Membership
Join Today
Event Agenda
Video
Careers
Search
About
Advertise
Advisory Board
Contact Us
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Onco'Zine
Advertisement #1
Home
Advertisement & Sponsorship Options
Download Our Media Kit
Continued Medical Education
Cancer A – Z
Drug Developmemt Technologies
A Novel Technology based on Somatic Hypermutation (SHM)
Editorial Advisory Board
Join Our Editorial Advisory Board
Contact Us
Terms and Conditions
Publications
ADC Review | J. Antibody-drug Conjugates
Resources for For Clinicians
Drug Map (ADC)
Peer Review Articles
The Review
Changing Strategies in the War on Cancer
Changing Strategies in the War on Cancer – Episode 1
Changing Strategies in the War on Cancer – Episode 2
Changing Strategies in the War on Cancer – Episode 3
Centers of the Cancer Universe: A Half-Century of Progress Against Cancer
Journal of CAR T-Cell Therapy
About CAR T-cells
Frequently Asked Questions
Types of Articles
Submit a Manuscript
The Onco’Zine Brief
The Network
The Episodes
How to Support The Onco’Zine Brief
Corporate Underwriting and Sponsorship
The Onco’Zine Dossier
Thalidomide: A History
Thalidomide: In the Shadow of Death
Controversy: The involvement of Ciba AG in the development of Thalidomide
Thalidomide’s Secret Past: The Link with Nazi Germany
Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer
Smoking and Health
New Surgeon General’s Report Presents the Unfiltered Truth About Tobacco
Smoking and the Lost Legacy of the First Surgeon General’s Report on Smoking and Health
Tobacco Control in the United States Has Saved 8 Million Lives In Last 50 Years
Tobacco Companies are Finally Moving Closer to Revealing the Truth about Smoking
The Harmful Effects of Smoking: The Public Denial in the Early-mid 1960s
Drug Approvals 2017 – 2020
Oncology & Hematology – FDA Drug Approvals 2018
Oncology & Hematology – FDA Drug Approvals 2019
Oncology & Hematology – FDA Drug Approvals 2020
Articles
Latest Articles
Expert Interviews
Editorials and Commentaries
Eric Rosenthal Reports
Publications
News
Business & Economics
Clinical Development
Conference Coverage
The Onco’Zine Brief
The Episodes
National Advertising
Agenda
Membership
Join Today
Event Agenda
Video
Careers
Trastuzumab Deruxtecan Is an Effective Option for Difficult-to-treat HER2-expressing Solid Tumors
Editorial Team
-
June 5, 2023
Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer
Study Shows Nivolumab Reduces Risk of Disease Progression in Advanced, Untreated Hodgkin Lymphoma
Adjuvant Osimertinib Significantly Improves Survival in Patients With Resected EGFR-Mutated NSCLC
Vorasidenib Significantly Improves Progression-free Survival in Grade 2 Glioma with IDH Mutation
FEATURED
It’s Time to Stop Talking About Cellular Therapy Disparities and Take Action
Jeffery J Auletta, MD
-
May 22, 2023
Accelerating Biologics R&D with Unified Software and Data Flows
Christian Olsen
-
May 20, 2023
“If I Can See It, I Can Kill It”
Andrew Pecora, MD, FACP, CPE
-
May 19, 2023
PBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention
Arthur Allen
-
May 11, 2023
The Road to the Clinic: BYON4228
Marco Timmers, Ph.D.
-
May 3, 2023
Getting back to Healthcare Basics: The Importance of Preventative Care Visits
Leia Spoor
-
April 25, 2023
Going Beyond the Guidance: Getting Business Benefit from Change Management
Michelle Anastasi
-
April 20, 2023
Therapy Onboarding Optimization: Why the Analytics of Patient Dropoff Requires a Closer Look
Yishai Knobel
-
April 10, 2023
Advertisement
NEWS
Trastuzumab Deruxtecan Is an Effective Option for Difficult-to-treat HER2-expressing Solid Tumors
Editorial Team
-
June 5, 2023
Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer
Editorial Team
-
June 4, 2023
Study Shows Nivolumab Reduces Risk of Disease Progression in Advanced, Untreated Hodgkin Lymphoma
Editorial Team
-
June 4, 2023
Adjuvant Osimertinib Significantly Improves Survival in Patients With Resected EGFR-Mutated NSCLC
Editorial Team
-
June 4, 2023
Vorasidenib Significantly Improves Progression-free Survival in Grade 2 Glioma with IDH Mutation
Editorial Team
-
June 4, 2023
Combination of Olaparib + Durvalumab Prolonged Progression-Free Survival in Advanced Ovarian Cancer
Editorial Team
-
June 3, 2023
What to expect at ASCO ’23: Lilly’s Progress in Treatment of Breast Cancer and...
Editorial Team
-
June 2, 2023
British Study Shows Black Women to be at Greater Risk of Dying from Uterine...
Editorial Team
-
June 1, 2023
What to Expect at ASCO ’23: A Trial In Progress Update of Mythic Therapeutics’...
Editorial Team
-
June 1, 2023
Study Shows that Only a Small Percentage of Cancer Research Funding Directly Benefits Patients
Editorial Team
-
June 1, 2023
How a Medical Recoding May Limit Cancer Patients’ Options for Breast Reconstruction
Rachana Pradhan
-
May 31, 2023
Mammograms at 40? Breast Cancer Screening Guidelines Spark Fresh Debate
Ronnie Cohen
-
May 30, 2023
CONFERENCE COVERAGE
Trastuzumab Deruxtecan Is an Effective Option for Difficult-to-treat HER2-expressing Solid Tumors
Editorial Team
-
June 5, 2023
Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer
Editorial Team
-
June 4, 2023
Study Shows Nivolumab Reduces Risk of Disease Progression in Advanced, Untreated Hodgkin Lymphoma
Editorial Team
-
June 4, 2023
Adjuvant Osimertinib Significantly Improves Survival in Patients With Resected EGFR-Mutated NSCLC
Editorial Team
-
June 4, 2023
Vorasidenib Significantly Improves Progression-free Survival in Grade 2 Glioma with IDH Mutation
Editorial Team
-
June 4, 2023
Combination of Olaparib + Durvalumab Prolonged Progression-Free Survival in Advanced Ovarian Cancer
Editorial Team
-
June 3, 2023
What to expect at ASCO ’23: Lilly’s Progress in Treatment of Breast Cancer and...
Editorial Team
-
June 2, 2023
What to Expect at ASCO ’23: A Trial In Progress Update of Mythic Therapeutics’...
Editorial Team
-
June 1, 2023
Prostate Cancer: Treatment Beyond the Standard of Care
Editorial Team
-
April 30, 2023
AUA 2023: Treating Prostate Cancer In Transgender Women
Editorial Team
-
April 30, 2023
ONS Congress: How Technology Can Advance Oncology Patient Care
Editorial Team
-
April 26, 2023
Combination of Olaparib + Ceralasertib Offers Clinical Benefit in DNA Repair-deficient Tumors
Editorial Team
-
April 21, 2023
Advertisement
EDITORIAL
It’s Time to Stop Talking About Cellular Therapy Disparities and Take Action
Jeffery J Auletta, MD
-
May 22, 2023
Accelerating Biologics R&D with Unified Software and Data Flows
Christian Olsen
-
May 20, 2023
Going Beyond the Guidance: Getting Business Benefit from Change Management
Michelle Anastasi
-
April 20, 2023
Therapy Onboarding Optimization: Why the Analytics of Patient Dropoff Requires a Closer Look
Yishai Knobel
-
April 10, 2023
Liquid Biopsy: Unlocking New Insights to Help Improve Outcomes for Cancer Patients
Craig Eagle, MD
-
February 15, 2023
Keeping Up with the Complexity of Compliance in Employee Health Benefits
Annie Bushey
-
February 8, 2023
ERIC ROSENTHAL REPORTS
Remembering Emil “Jay” Freireich—the Man Who Made Vince DeVita a ‘Believer’
Eric T. Rosenthal
-
February 13, 2021
Why Were Top HHS Officials? Interviews Thwarted by Their Press Offices?
Eric T. Rosenthal
-
March 5, 2019
EXPERT INTERVIEWS
Stephen Spellman: Mismatched Unrelated Donors – Key to Erasing the Gap in Donor Availability...
Editorial Team
-
January 18, 2023
Susanna Greer, Ph.D.: Advancing Funding for Cutting-edge Cancer Research
Editorial Team
-
November 29, 2022
The Onco’Zine Brief: A Novel Approach to Advancing Breast Cancer Therapy
Editorial Team
-
October 26, 2022
X